Recommended as Stock of the Week on January 3, 2026

IQVIA - The invisible engine behind every new drug

TickerIQV.NYSE
Recommended Price225.37 USD
Current Price 225.37 USD
IQVIA Holdings Inc – stock chart

Scores at time of recommendation (January 3, 2026)

Leeway Score
65/100
Excellent
Business Rating
81/100
Excellent
Market-Fit Rating
53/100
Fair
Cycle Rating
62/100
Fair

More about our scores in Help

5-year stock timeline

IQVIA (IQV.NYSE) — Timeline 2020–2026

2020: COVID disruption and recovery Early-2020 saw IQVIA's R&D Solutions business take a sharp hit as COVID-19 spread, prompting the company to lower guidance in Q1. The picture shifted by mid-year. Stronger execution and incremental COVID trial work in Q2–Q3 led management to raise full-year outlook, and the stock recovered as investors recognized the company's ability to convert backlog into revenue.

2021–2022: Normalization and capability expansion Clinical activity returned to normal rhythms, and IQVIA converted its substantial backlog into revenue. The company pursued targeted M&A to deepen its commercial analytics and omnichannel reach, notably acquiring Lasso Marketing in Q3 2022. This period established IQVIA as a resilient, cash-generative business with durable clinical and commercial revenue streams.

2023–2025: Margin expansion and shareholder returns IQVIA shifted focus toward operational leverage and capital allocation. The company executed large share repurchases while investing meaningfully in AI and discovery capabilities. Strong results in 2024–2025 and reaffirmed guidance reinforced confidence in the margin-expansion thesis.

February 2026: Discovery assets acquisition IQVIA agreed to acquire Charles River's discovery assets for approximately $145 million, extending its AI-enabled small-molecule and NAM capabilities. This move signals a clear repositioning toward higher-margin, technology-driven services and marks a meaningful catalyst for the next phase of growth.

Current backdrop (March 2026) The market has gradually reframed IQVIA from a pandemic-resilience story into a cash-generative, AI-enabled life-sciences infrastructure play. Margin improvement, disciplined buybacks, and strategic M&A have supported a sustained re-rating. At 166.09, the stock reflects this repositioning and the momentum behind discovery-asset expansion.

Key Points

From recommendation (January 3, 2026)

  • Market leader for clinical trials and healthcare data with 32.4 billion USD Order backlog
  • Book-to-bill ratio of 1.15x signals continued strong demand
  • Strategic partnership with AWS for AI-powered healthcare platform
  • ROE of 19.4% well above the life sciences average of 12
  • Share buybacks of 1.03 billion USD in nine months 2025

Investment Thesis

From recommendation (January 3, 2026)

IQVIA is the backbone of modern drug development - a position the company has built up over decades through the combination of a unique database, operational excellence and deep customer relationships. Without IQVIA, pharmaceutical companies would simply not be able to get new drugs through the complex regulatory processes. The recent AWS partnership and the settlement of the legal dispute with Veeva Systems create additional growth prospects, while the order backlog of USD for multi-year sales visibility. With a PEG of 0.96 and expected EPS growth rates of 6.9% (2025) and 8.4% (2026), the share offers a valuation below the growth momentum - a rare setup for an infrastructure champion in the healthcare sector.

Key risks and downside factors

IQVIA operates globally across three segments—R&D, Technology & Analytics, and contract sales—providing analytics, technology and contract research services to pharmaceutical, biotech and healthcare companies. Its competitive landscape includes established contract research organizations and life-science tools providers like Thermo Fisher Scientific, Charles River Laboratories and ICON plc, all vying for share in clinical development, lab services and data analytics. The business carries meaningful risks worth watching. Client and contract concentration matter here—no single customer should dominate revenue. Regulatory and privacy scrutiny around patient-level data handling has teeth and will likely intensify. Margins also feel pressure from two directions: competitors willing to undercut on price, and the cyclical nature of clinical-trial volumes, which swing with pharmaceutical R&D spending patterns. When trials slow, utilization drops and margins compress quickly.

  • Revenue tends to swing based on a handful of large pharmaceutical clients and how their long-term contracts happen to land in any given period [18].
  • Regulatory, legal, and reputational risk stemming from the collection, use, and sale of anonymized patient-level data.
  • Competitive pressure from large CROs and life-science services firms threatens to compress pricing and erode market share [5].
  • Operational execution and trial-volume exposure—site recruitment bottlenecks and trial delays—can compress margins when macroeconomic conditions tighten.

Competitive landscape

IQVIA operates as a dominant global provider of advanced analytics, technology solutions, and clinical research services across the life sciences industry. Its competitive set spans large contract research organizations and scientific tools and data companies—Thermo Fisher, Charles River, ICON, and Veeva among them—each competing across CRO services, lab services, and commercial analytics. The business faces meaningful headwinds: regulatory and data-privacy constraints limit what can be done with real-world data, cyclical spending patterns in biopharma R&D create lumpy demand for CRO services, and competition remains fierce enough to pressure both pricing and margins, particularly as clients demand tighter technology integration.

CompanyTicker
Thermo Fisher Scientific Inc.TMO.NYSE
Veeva Systems Inc.VEEV.NYSE
ICON plcICLR.NASDAQ
Charles River Laboratories International, Inc.CRL.NYSE

Private competitors

  • Parexel
  • Syneos Health

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Catalysts

From recommendation (January 3, 2026)

  • Integration of the AWS partnership in commercial offerings and AI platform
  • Veeva cooperation could accelerate software and data integration
  • EPS forecasts for 2026 at USD 12.94 (+8.8% compared to 2025)
  • Sustained high RFP volume (+20% YoY) signals industry recovery
  • Further share buybacks with solid free cash flow generation

Analysis

From recommendation (January 3, 2026)

IQVIA benefits from a position that is virtually unrivaled: the company controls access to critical real-world data and has the operational infrastructure to conduct complex clinical trials worldwide - both essential for any pharmaceutical company looking to bring a new drug to market. The barriers to entry in this business are extremely high, as decades of data accumulation, regulatory expertise and customer trust cannot be replicated overnight. However, the market is not free of competition: established CROs such as Thermo Fisher (PPD), ICON, Syneos Health and Parexel also hold significant shares, which leads to a challenging price environment. With net debt of 3.52x and operating margin pressure, IQVIA is certainly under financial pressure. Nevertheless, the combination of a solid book-to-bill ratio, strategic AWS partnership and aggressive share buybacks suggests robust operating momentum. The ROE of just under 20% underlines the fact that the management and business model efficiently convert capital into earnings - a quality feature that has become rare in the current market environment.

Performance Figures of IQVIA Holdings Inc

in USD

1M High / Low
182.93 / 162.22
52W High / Low
247.05 / 134.65
5Y High / Low
285.61 / 134.65
1M
-2.14%
3M
-24.34%
6M
-17.47%
1Y
-0.41%
3Y
-14.25%
5Y
-13.89%

Relative Performance vs Benchmarks

PeriodIQVIA Holdings Inc vs DAX vs S&P 500 (SPY)
1M -2.14% +3.83% +2.85%
3M -24.34% -18.94% -19.97%
6M -17.47% -12.50% -15.20%
1Y -0.41% -3.19% -17.67%
3Y -14.25% -62.48% -79.33%
5Y -13.89% -67.24% -87.71%

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

PeriodP/E RatioP/S RatioP/B RatioP/CF Ratio
Current21.61.84.511.0
1Y ago23.42.05.311.3
3Y ago35.62.66.317.3
5Y ago92.13.16.314.1

Frequently Asked Questions

From recommendation (January 3, 2026)

Is IQVIA - The invisible engine behind every new drug a good investment?

IQVIA - The invisible engine behind every new drug has a Leeway Score of 65.4/100, which is rated as Excellent. The Leeway Score combines business quality, fundamental evaluation, and valuation cycle into a comprehensive assessment. A higher score indicates stronger investment quality based on AI-powered fundamental analysis.

What does IQVIA - The invisible engine behind every new drug do?

IQVIA - The invisible engine behind every new drug is a company characterized by the following investment thesis: IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina. IQVIA Holdings Inc operates in the Healthcare / Diagnostics & Research industry is based in USA employs around 93,000 people. IQVIA Holdings Inc recently reported revenue of about 16.31B USD, a profit margin of 8.34%, return on equity of 21.44%, a market capitalisation around 28.20B USD, valuation multiples of roughly 21.2x earnings, 1.7x sales, 4.3x book value. Analyst consensus currently expects earnings per share of around 14.08 USD with year‑over‑year growth of 10.87%.

What are the key metrics for IQV.NYSE?

Key metrics for IQV.NYSE include valuation (P/E 30.2, P/S 2.4, P/B 6.3), profitability (profit margin 8.07%, ROE 19.37%), and growth (revenue 5.20%, earnings 24.50%). Market capitalization is 38.70B USD. These metrics give an overview of the company's financial performance and valuation.

How has IQVIA - The invisible engine behind every new drug's stock price performed?

IQVIA - The invisible engine behind every new drug's stock has returned — over 1 year, — over 3 years, and — over 5 years. Performance can vary depending on market conditions and company developments.

How is IQV.NYSE valued?

IQV.NYSE has the following valuation metrics: P/E Ratio: 30.2, P/S Ratio: 2.4, P/B Ratio: 6.3. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

What are the growth catalysts for IQVIA - The invisible engine behind every new drug?

The key growth catalysts for IQVIA - The invisible engine behind every new drug are:
  • Integration of the AWS partnership in commercial offerings and AI platform
  • Veeva cooperation could accelerate software and data integration
  • EPS forecasts for 2026 at USD 12.94 (+8.8% compared to 2025)
  • Sustained high RFP volume (+20% YoY) signals industry recovery
  • Further share buybacks with solid free cash flow generation
These factors can positively influence the company's future growth and performance.

What are the key risks when investing in IQV.NYSE?

Key risks for IQV.NYSE include: IQVIA operates globally across three segments—R&D, Technology & Analytics, and contract sales—providing analytics, technology and contract research services to pharmaceutical, biotech and healthcare companies. Its competitive landscape includes established contract research organizations and life-science tools providers like Thermo Fisher Scientific, Charles River Laboratories and ICON plc, all vying for share in clinical development, lab services and data analytics. The business carries meaningful risks worth watching. Client and contract concentration matter here—no single customer should dominate revenue. Regulatory and privacy scrutiny around patient-level data handling has teeth and will likely intensify. Margins also feel pressure from two directions: competitors willing to undercut on price, and the cyclical nature of clinical-trial volumes, which swing with pharmaceutical R&D spending patterns. When trials slow, utilization drops and margins compress quickly.
  • Revenue tends to swing based on a handful of large pharmaceutical clients and how their long-term contracts happen to land in any given period [web:18].
  • Regulatory, legal, and reputational risk stemming from the collection, use, and sale of anonymized patient-level data.
  • Competitive pressure from large CROs and life-science services firms threatens to compress pricing and erode market share [web:5].
  • Operational execution and trial-volume exposure—site recruitment bottlenecks and trial delays—can compress margins when macroeconomic conditions tighten.
Investors should consider these risk factors carefully before making an investment decision.

Who are the main competitors of IQVIA - The invisible engine behind every new drug?

IQVIA - The invisible engine behind every new drug competes with several listed peers in its sector. IQVIA operates as a dominant global provider of advanced analytics, technology solutions, and clinical research services across the life sciences industry. Its competitive set spans large contract research organizations and scientific tools and data companies—Thermo Fisher, Charles River, ICON, and Veeva among them—each competing across CRO services, lab services, and commercial analytics. The business faces meaningful headwinds: regulatory and data-privacy constraints limit what can be done with real-world data, cyclical spending patterns in biopharma R&D create lumpy demand for CRO services, and competition remains fierce enough to pressure both pricing and margins, particularly as clients demand tighter technology integration.
  • Thermo Fisher Scientific Inc. (TMO.NYSE)
  • Veeva Systems Inc. (VEEV.NYSE)
  • ICON plc (ICLR.NASDAQ)
  • Charles River Laboratories International, Inc. (CRL.NYSE)
These competitors influence pricing power, growth opportunities and relative valuation.

When does IQVIA - The invisible engine behind every new drug report earnings?

IQVIA - The invisible engine behind every new drug's next earnings report date is April 23, 2026.

Key Metrics

From recommendation (January 3, 2026)

Market Capitalization
38.70B USD
P/E Ratio
30.16
Analyst Target Price
253.95 USD

Valuation Metrics

P/S Ratio
2.43
P/B Ratio
6.28

Profitability Metrics

Profit Margin
8.07%
Operating Margin
13.98%
Return on Equity
19.37%
Return on Assets
5.07%

Growth Metrics

Revenue Growth
5.20%
Earnings Growth
24.50%

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

No dividend data available.

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Historical earnings performance

94.2%
Beat estimate
5.8%
Miss estimate
+4.49%
Avg surprise when beat
-43.42%
Avg surprise when miss

Reports analyzed: 52

Upcoming earnings report

April 23, 2026
Next earnings date

Analyst estimates for upcoming periods

Next year
December 31, 2027
Consensus14.08
Range13.65 – 14.88
22 analysts
Est. growth vs prior: 10.87%
Revisions: 7d ↑2 ↓0 · 30d ↑4 ↓4
Next quarter
June 30, 2026
Consensus3.02
Range2.88 – 3.13
19 analysts
Est. growth vs prior: 7.38%
Revisions: 7d ↑1 ↓0 · 30d ↑2 ↓0

Key financial figures

All figures in USD

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.

20252024202320222021
Revenue16.31B15.40B14.98B14.41B13.87B
Operating income (EBIT)2.29B2.20B1.98B1.80B1.39B
Net income1.36B1.37B1.36B1.09B966.00M
Free cash flow2.05B2.11B1.50B1.59B2.30B
Total assets29.94B26.90B26.68B25.34B24.69B
Equity6.50B6.07B6.11B5.76B6.04B
Net debt14.19B12.45B12.52B11.79B11.07B

Unlock Premium

  • Weekly top picks
  • 25,000+ stock analyses
  • AI-powered ratings
Start Free Trial

Cancel anytime

Full Analysis

Detailed fundamental analysis of this stock

View Full Analysis

Want More of This?

Get a hand-picked stock recommendation with detailed analysis every week

View Stock of the Week
General Terms and Conditions
© Leeway
PWP Leeway UG (haftungsbeschränkt)
Leeway Icon